Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QR12000 compound tablet vs sacubitril/valsartan in moderate to severe primary hypertension
CTR20244399Phase 3Active
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd.
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of QR12000 in essential hypertension, sponsored by Wuhan Createrna Science and Technology Co., Ltd.. Started Feb 2025; status: active.
02
Drugs
QR12000
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20244399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244399.